Gracell Biotechnologies Inc. (GRCL) Stock Analysis
DELISTED 2024
What happened to Gracell Biotechnologies Inc. (GRCL) stock?
Gracell Biotechnologies Inc. (GRCL) no longer trades on public markets. It was delisted in February 2024. The figures below are historical and are not a current quote.
- Status:
- Delisted — no longer trades
- Delisting date:
- February 2024
- Last recorded price (historical):
- $10.25 (last quote on record before the February 2024 delisting; historical, not a current quote)
Market cap $198M is the value of all shares combined.
For informational purposes only. Not financial advice. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Gracell Biotechnologies Inc. (GRCL). Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for cancer treatment, primarily in China. Their pipeline includes FasTCAR and TruUCAR technology platforms targeting various hematological malignancies and solid tumors.
Last analyzed: Mar 16, 2026Gracell Biotechnologies Inc. (GRCL) Healthcare & Pipeline Overview
Gracell Biotechnologies Inc. ADR Information Sponsored
Gracell Biotechnologies Inc. (GRCL) trades in the U.S. as an American Depositary Receipt (ADR).
- ADR Level: 2
- ADR Ratio: 1:1
More about this archive record
Can I still buy GRCL shares?
No. GRCL stopped trading on public markets in February 2024, so the shares are not available through a broker. Anything you see quoted for GRCL elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before GRCL stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Gracell Biotechnologies Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.